SCHEDULE: AtaiBeckley Inc. Merger Agreement and Shareholder Support

AtaiBeckley Inc. announces a merger agreement with Eli Lilly and Company, with key shareholders Apeiron Investment Group Ltd. and Christian Angermayer entering into voting and support agreements.

Summary

• AtaiBeckley Inc. has entered into an Agreement and Plan of Merger with Eli Lilly and Company and its subsidiary Albali Acquisition Corporation.
• The merger will result in AtaiBeckley Inc. becoming a wholly owned subsidiary of Eli Lilly and Company.
• Key shareholders, Apeiron Investment Group Ltd. and Christian Angermayer, have signed Voting and Support Agreements with Eli Lilly and Company.
• These agreements require Apeiron and Angermayer to vote their shares in favor of the merger, refrain from transferring shares, and adhere to other restrictions.
• As of June 22, 2026, the reporting persons collectively beneficially own 56,812,134 shares, representing approximately 15.4% of the voting rights.
• The ownership percentages are based on 368,166,674 shares outstanding as of May 8, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development due to the definitive merger agreement with a major pharmaceutical company, indicating a likely successful exit for shareholders, though the exact terms of the merger are not detailed here.

Positives

• The company has secured a merger agreement with a major pharmaceutical company, Eli Lilly and Company.
• Key shareholders have committed to supporting the merger through voting and support agreements, indicating strong alignment.
• The transaction is structured as a merger where AtaiBeckley Inc. will become a wholly owned subsidiary, suggesting a potentially favorable outcome for the company and its shareholders.

Risks

• The merger is subject to the satisfaction or waiver of certain conditions outlined in the Merger Agreement.
• Shareholders are not third-party beneficiaries under the Support Agreements and should not rely on representations and warranties as factual conditions.
• Information concerning the subject matter of representations and warranties may change after the date of the Support Agreements, potentially impacting the transaction.

Future Outlook

The filing primarily concerns a merger agreement and shareholder support, indicating a significant future event for the company. Specific forward-looking financial guidance is not provided in this Schedule 13D amendment.

Management Comments

• The Support Agreements provide that, among other things, each of Apeiron and Christian Angermeyer has agreed (i) to vote all of the shares of common stock held by such stockholder in favor of the adoption of the Merger Agreement, subject to certain exceptions (including the valid termination of the Merger Agreement), (ii) not to transfer such shares of common stock, and (iii) to certain other restrictions on its ability to take actions with respect to the Company and its shares of common stock.

Industry Context

StockSavvy.ai notes that this filing signifies a major consolidation event in the biotechnology or pharmaceutical sector, with a larger entity (Eli Lilly and Company) acquiring a smaller one (AtaiBeckley Inc.). Such M&A activity is common in the industry, driven by pipeline advancements, market access, or strategic portfolio adjustments.

Stakeholder Impact

• Shareholders: Likely to receive a payout or exchange of shares as part of the merger, subject to the terms of the Merger Agreement.
• Employees: Potential for changes in employment status or roles following the acquisition by Eli Lilly and Company.
• Creditors: The merger may impact existing debt obligations and covenants of AtaiBeckley Inc.

Next Steps

• Shareholder vote on the adoption of the Merger Agreement.
• Satisfaction or waiver of conditions precedent to closing the merger.
• Completion of the merger, making AtaiBeckley Inc. a wholly owned subsidiary of Eli Lilly and Company.

Key Dates

Recommendation

The filing confirms a merger agreement, which is a significant event. However, without the specific terms of the merger (e.g., acquisition price, exchange ratio), a definitive buy or sell recommendation is premature. Investors should hold to await further details on the transaction's financial implications.

Keywords

AtaiBeckley Inc., Eli Lilly and Company, Merger Agreement, Schedule 13D, Voting and Support Agreement, Shareholder, Acquisition, SEC Filing